DK174811B1 - Stabiliserede humanproteinpræparater samt fremgangsmåde til fremstilling deraf - Google Patents

Stabiliserede humanproteinpræparater samt fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK174811B1
DK174811B1 DK198804831A DK483188A DK174811B1 DK 174811 B1 DK174811 B1 DK 174811B1 DK 198804831 A DK198804831 A DK 198804831A DK 483188 A DK483188 A DK 483188A DK 174811 B1 DK174811 B1 DK 174811B1
Authority
DK
Denmark
Prior art keywords
human protein
erythropoietin
composition according
preparation
epo
Prior art date
Application number
DK198804831A
Other languages
Danish (da)
English (en)
Other versions
DK483188A (da
DK483188D0 (da
Inventor
Fritz Demmer
Werner Gruber
Heinrich Woog
Hans-Joerg Markl
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of DK483188D0 publication Critical patent/DK483188D0/da
Publication of DK483188A publication Critical patent/DK483188A/da
Application granted granted Critical
Publication of DK174811B1 publication Critical patent/DK174811B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DK198804831A 1987-09-05 1988-08-30 Stabiliserede humanproteinpræparater samt fremgangsmåde til fremstilling deraf DK174811B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873729863 DE3729863A1 (de) 1987-09-05 1987-09-05 Stabilisierte erythropoietin-lyophilisate
DE3729863 1987-09-05

Publications (3)

Publication Number Publication Date
DK483188D0 DK483188D0 (da) 1988-08-30
DK483188A DK483188A (da) 1989-03-06
DK174811B1 true DK174811B1 (da) 2003-12-01

Family

ID=6335375

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198804831A DK174811B1 (da) 1987-09-05 1988-08-30 Stabiliserede humanproteinpræparater samt fremgangsmåde til fremstilling deraf

Country Status (29)

Country Link
US (1) US4992419A (ru)
EP (1) EP0306824B1 (ru)
JP (1) JPH0780782B2 (ru)
KR (1) KR960009929B1 (ru)
CN (1) CN1027224C (ru)
AT (1) ATE77556T1 (ru)
AU (1) AU610636B2 (ru)
CA (1) CA1330301C (ru)
CS (1) CS274681B2 (ru)
DD (1) DD273004A5 (ru)
DE (2) DE3729863A1 (ru)
DK (1) DK174811B1 (ru)
ES (1) ES2051806T3 (ru)
FI (1) FI93517C (ru)
GR (1) GR3005454T3 (ru)
HK (1) HK89495A (ru)
HU (1) HU202761B (ru)
IE (1) IE60310B1 (ru)
IL (1) IL87628A (ru)
LV (1) LV10178B (ru)
MX (1) MX12880A (ru)
NO (1) NO178687C (ru)
NZ (1) NZ225975A (ru)
PH (1) PH25618A (ru)
PL (1) PL157944B1 (ru)
PT (1) PT88417B (ru)
RU (2) RU2043118C1 (ru)
UA (2) UA26855C2 (ru)
ZA (1) ZA886528B (ru)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4014654A1 (de) * 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
EP0582933A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
JP2747979B2 (ja) * 1994-08-19 1998-05-06 雪印乳業株式会社 ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5916597A (en) * 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US20030138402A1 (en) * 1995-12-25 2003-07-24 Otsuka Pharmaceutical Co., Ltd. Dry compositions
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
SK284989B6 (sk) * 1996-12-24 2006-04-06 Biogen, Inc. Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren
US6548296B1 (en) * 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
PT986644E (pt) * 1997-07-23 2007-01-31 Roche Diagnostics Gmbh Preparação de eritropoietina por activação genética endógena com promotores virais
EP0965349A1 (de) * 1998-06-18 1999-12-22 Roche Diagnostics GmbH Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
AR019025A1 (es) * 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
EP1181036B1 (en) * 1999-04-09 2008-07-23 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical compositions of erythropoietin
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
EP1232753B1 (en) * 1999-09-08 2008-03-19 Chugai Seiyaku Kabushiki Kaisha Stable protein solution filled in a container made from a hydrophobic resin and method of stabilizing the same
PT1311285E (pt) * 2000-05-15 2005-06-30 Hoffmann La Roche Composicao farmaceutica liquida contendo um derivado de eritropoietina
AU2005225151B2 (en) * 2000-05-15 2008-05-29 F. Hoffmann-La Roche Ag New pharmaceutical composition
AU2001277781A1 (en) * 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
SI21257A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
WO2004108152A1 (en) * 2003-06-10 2004-12-16 Lg Life Sciences Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
KR100560697B1 (ko) * 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
EA010650B1 (ru) * 2003-09-29 2008-10-30 Уоррен Фармасьютикалз, Инк. Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
PE20151205A1 (es) * 2008-08-15 2015-08-31 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral
WO2011017502A2 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
DK2521561T3 (en) * 2009-11-03 2017-09-11 Ironwood Pharmaceuticals Inc LINACLOTID FOR TREATMENT OF CHRONIC CONSTIPATION
JP5638628B2 (ja) * 2010-01-19 2014-12-10 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． 持続型エリスロポエチン結合体の液剤
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
EP3626253B8 (en) 2010-08-11 2022-04-20 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
PL2776055T3 (pl) 2011-08-17 2017-06-30 Ironwood Pharmaceuticals, Inc. Sposoby leczenia zaburzeń żołądkowo-jelitowych
EA022327B1 (ru) * 2013-01-04 2015-12-30 Общество С Ограниченной Ответственностью "Рубикон" Инъекционное ветеринарное средство в форме раствора для борьбы с полиинвазиями животного и способ его получения
US10052361B2 (en) 2014-03-29 2018-08-21 Intas Pharmaceuticals Ltd Liquid pharmaceutical composition of conjugated erythropoietin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
EP0214281B1 (en) * 1985-03-06 1992-09-09 Survival Technology, Inc. Protein absorption enhancing agents

Also Published As

Publication number Publication date
FI93517B (fi) 1995-01-13
ZA886528B (en) 1989-05-30
IL87628A0 (en) 1989-01-31
LV10178A (lv) 1994-10-20
DE3872334D1 (de) 1992-07-30
RU2043118C1 (ru) 1995-09-10
AU2173988A (en) 1989-04-27
DK483188A (da) 1989-03-06
HU202761B (en) 1991-04-29
NZ225975A (en) 1991-07-26
HUT47863A (en) 1989-04-28
GR3005454T3 (ru) 1993-05-24
IE60310B1 (en) 1994-06-29
KR890004718A (ko) 1989-05-09
DK483188D0 (da) 1988-08-30
UA26123A (uk) 1999-06-07
HK89495A (en) 1995-06-16
CS274681B2 (en) 1991-09-15
RU2100032C1 (ru) 1997-12-27
CN1031801A (zh) 1989-03-22
DD273004A5 (de) 1989-11-01
NO178687B (no) 1996-02-05
NO178687C (no) 1996-05-15
KR960009929B1 (ko) 1996-07-25
EP0306824A2 (de) 1989-03-15
FI884051A0 (fi) 1988-09-02
US4992419A (en) 1991-02-12
PL274485A1 (en) 1989-04-17
EP0306824A3 (en) 1990-01-31
PH25618A (en) 1991-08-08
CA1330301C (en) 1994-06-21
PT88417A (pt) 1989-07-31
JPS6471818A (en) 1989-03-16
EP0306824B1 (de) 1992-06-24
PL157944B1 (en) 1992-07-31
FI884051A (fi) 1989-03-06
CN1027224C (zh) 1995-01-04
FI93517C (fi) 1995-04-25
ES2051806T3 (es) 1994-07-01
NO883926D0 (no) 1988-09-02
ATE77556T1 (de) 1992-07-15
IL87628A (en) 1993-07-08
PT88417B (pt) 1992-10-30
MX12880A (es) 1993-12-01
JPH0780782B2 (ja) 1995-08-30
NO883926L (no) 1989-03-06
UA26855C2 (ru) 1999-12-29
DE3729863A1 (de) 1989-03-16
LV10178B (en) 1995-04-20
CS590188A2 (en) 1990-12-13
AU610636B2 (en) 1991-05-23
IE882671L (en) 1989-03-05

Similar Documents

Publication Publication Date Title
DK174811B1 (da) Stabiliserede humanproteinpræparater samt fremgangsmåde til fremstilling deraf
JP4789698B2 (ja) 因子ｉｘ用処方
DK167048B1 (da) Stabilt interferonkompleks, farmaceutisk praeparat indeholdende dette samt fremgangsmaade til fremstilling af interferonkomplekset
AU2010321225B2 (en) Formulation for hGH and rhIGF-1 combination
KR20100061868A (ko) 아연을 전혀 포함하지 않거나 소량의 아연만을 포함한 개선된 안정성을 가지는 인슐린 제형
JP5253501B2 (ja) 安定化トロンビン組成物
JP2006257099A (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
CA2528988C (en) Stable, aqueous solution of human erythropoietin, not containing serum albumin
JP2003504346A (ja) 成長ホルモン製剤
ES2292103T3 (es) Formulacion liquida de eritropoyetina.
KR100560697B1 (ko) 알부민을 함유하지 않는 에리스로포이에틴 제제
CN102233130B (zh) 稳定的含有胸腺肽1衍生物的药物制剂
CN112004522A (zh) 使用葡甲胺盐稳定包含蛋白的制剂的方法
US20130149293A1 (en) Stable compositions of factor ix
WO2016059593A1 (en) Stable injectable composition of protein drugs and process for its preparation
JPH0352821A (ja) 安定化された粉末状カルシトニン類医薬組成物